12 unknown. 12 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Unknown 12 |
Follow Test: new trials by email Literature Review of Test trials Research Report on Test
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201 UI059, UIC202201 - Gastro-Intestinal Disorder | Phase 1 | Unknown | Korea United Pharm. Inc. | 66 | 2024-07-03 | 2024-05-01 |
| Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-22 | 2023-09-06 |
| Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 250/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-01 | 2023-08-31 |
| Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS 100/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-02-17 | 2023-03-09 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS - Asthma, Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 36 | 2022-05-11 | 2022-05-31 |
| Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test, Reference - Bioequivalence, Asthma | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 18 | 2021-10-01 | 2021-10-20 |
| A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals, FLOVENT DISKUS - Asthma, Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 50 | 2021-08-13 | 2021-08-26 |
| Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects D418 Tab., CKD-388 Tab. - Chronic Hepatitis b | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 56 | 2021-02-26 | 2020-12-21 |
| A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test, Reference - Bioequivalence, Asthma | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 50 | 2021-01-18 | 2021-04-20 |
| Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506 YYC506-T and YYC506-A (phase 1), YYC506 (phase 1), YYC506-T and YYC506-A (phase 2) - Dyslipidemias | Phase 1 | Unknown | Yooyoung Pharmaceutical Co., Ltd. | 60 | 2021-01-07 | 2021-05-05 |
| Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers CKD-330 Tab. and D090 Tab., CKD-333 Tab. - Cardiovascular Disease | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 51 | 2020-11-11 | 2020-11-02 |
| Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers CKD-330 Tab. and D086 Tab., CKD-333 Tab. - Cardiovascular Disease | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 51 | 2020-07-14 | 2020-07-22 |
Asthma (4) · Cardiovascular Diseases (2) · Digestive System Diseases (1) · Dyslipidemias (1) · Hepatitis B, Chronic (1)
Respirent Pharmaceuticals Co Ltd. (7) · Chong Kun Dang Pharmaceutical (3) · Korea United Pharm. Inc. (1) · Yooyoung Pharmaceutical Co., Ltd. (1)
Greece (7) · South Korea (5)
Chrysoula Doxani, MD, MSc, PhD (5) · Chrysoula Doxani, Dr. (1) · Ioannis Stefanidis, Professor (1) · Min Kyu Park, PhD (1) · Minkyu Park, MD, PhD (1)